

**MISSISSIPPI DIVISION OF MEDICAID**  
**Pharmacy & Therapeutics Committee**  
**Live Meeting**  
**May 9, 2023**  
**10:00am to 5:00pm**

**AGENDA**

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of February 14, 2023 Meeting Provisional Decisions and Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Drug Class Announcements
- VII. Public Comment
- VIII. Therapeutic Class Review Additions  
Anti-Obesity Select Agents
- IX. New Drug/New Generic Reviews
  - a. Alzheimer's Agents- Leqembi (lecanemab)
  - b. Antibiotics & Related, GI- Rebyota (fecal microbiota)
  - c. Antibiotics, Vaginal- Xaciato gel (clindamycin) *Financial Review only*
  - d. Antineoplastics
    - i. Jaypirca (pirtonrutinib)
    - ii. Lytgobi (futibatnib)
    - iii. Krazati (adagrasib)
    - iv. Rezlidhia (olutasidenib)
  - e. Antiretroviral- Sunlenca (lenacapavir)
  - f. Colony Stimulating Factor
    - i. Rolvedon (eflapegrastim)
    - ii. Stimufend (pegfilgrastim) *Financial Review only*
  - g. Cytokine & CAM Antagonists- Amjevita (adalimumab) *Financial Review only*
  - h. Factor Deficiency Agents- Hemgenix (etranacogene dezaparvovec)
  - i. Multiple Sclerosis
    - i. Briumvi (ublituximab)
    - ii. Tascenso ODT (fingolimod) *Financial Review only*
  - j. Ophthalmic Allergic Conjunctivitis- Verkazia (cyclosporine)
  - k. Stimulants- Xelstryl (dextroamphetamine) patch *Financial Review only*
- X. Division of Medicaid Update
- XI. Next Meeting Dates
  - a. Tuesday, August 8, 2023
  - b. Tuesday, October 24, 2023
- XII. Adjournment